What can be done about hot flushes after treatment for breast cancer?

Climacteric

Volumn 13, Issue 1, 2010, Pages 4-21

  Kontos, M ^a   Agbaje, O F ^b   Rymer, J ^c   Fentiman, I S ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Desvenlafaxine; Hot flushes; Stellate ganglion block; Tamoxifen; Tibolone

Indexed keywords

ANGELICA SINENSIS EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DESVENLAFAXINE; ESTROGEN; FLUOXETINE; GABAPENTIN; GESTAGEN; HUMULUS LUPULUS EXTRACT; ISOFLAVONE DERIVATIVE; MATRICARIA CHAMOMILLA EXTRACT; MEDROXYPROGESTERONE ACETATE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; TIBOLONE; TRISEQUENS; VENLAFAXINE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANGELICA SINENSIS; APPETITE; AROMATHERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CHINESE HERB; CHINESE MEDICINE; CIMICIFUGA RACEMOSA; CLINICAL ASSESSMENT; CONSTIPATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FATIGUE; HEADACHE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HUMULUS LUPULUS; INSOMNIA; MATRICARIA; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOMNOLENCE; STELLATE GANGLION BLOCK; UNSTEADINESS; VASOMOTOR DISORDER; XEROSTOMIA; YOGA;

AMINES; ANESTHETICS, LOCAL; BREAST NEOPLASMS; BUPIVACAINE; CLONIDINE; COMPLEMENTARY THERAPIES; CYCLOHEXANECARBOXYLIC ACIDS; DRUGS, CHINESE HERBAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXERCISE; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; MIDDLE AGED; NOREPINEPHRINE; PROGESTERONE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; STELLATE GANGLION; SURVIVORS;

EID: 75149157076     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130903291058     Document Type: Review

References (121)

1. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psycho-Oncology 2004;13:769-778
2. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006;9:49-58
3. Kronenberg F. Hot flushes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-336
4. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99: 1763-1768
5. Cuzick J, Sestak I, Cella D, Fallowfield L; ATAC Trialists' Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008;9:1143-1148
6. Fentiman IS, Allen D,Wheeler M, Rymer J. The influence of premenopausal hormones on severity of climacteric symptoms and use of HRT. Climacteric 2006;9:135-145
7. Gast GC, Grobbee DE, Pop VJ, et al. Vasomotor symptoms are associated with a lower bone density. Menopause 2009;16:231-238
8. Crandall CJ, Zheng Y, Crawford SL, et al. Presence of vasomotor symptoms is associated with lower bone mineral density: a longitudinal analysis. Menopause 2009;16:239-246
9. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flushes. Systematic review and meta-analysis. J AmMed Assoc 2006;295:2057-2071
10. Carroll DG. Nonhormonal therapies for hot flushes in menopause. Am Fam Physician 2006;73:457-464
11. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidencebased review. Arch Gynecol Obstet 2007;276: 463-469
12. Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flushes in breast cancer survivors: an evidencebased review. Clin Ther 2007;29:230-241
13. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
14. Beral V. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427
15. Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455 (Pubitemid 38210063)
16. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953; 13:688-703
17. Alder E. The Blatt-Kupperman menopausal index: a critique. Maturitas 1998;29:19-24
18. Wiklund I, Holst J, Karlberg J, et al. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-224
19. Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31
20. Hunter M, Battertsby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas 1986;8:217-228
21. Hilditch JR, Lewis J, Pater A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175
22. Schneider HPG, Heinemann LAG, Mohner S, et al. Menopause Rating Scale (MRS). Reliability of scores and menopausal complaints. Climacteric 2000;3:59-64
23. Carpenter JS, Monahan PO, Azzouz F. Accuracy of subjective hot flush reports compared with continuous sternal skin conductance monitoring. Obstet Gynecol 2004;104:1322-1326
24. Farquhar C, Majoribanks J, Lethaby A, et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009 Apr 15;(2):CD004143
25. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-1854
26. Vestergaard P, Hermann AP, Stilgren L, et al. Effects of hormonal replacement therapy on menopausal symptoms and blood pressure-a randomised controlled trial. Maturitas 2003; 46:123-132
27. Holmberg L, Iversen O-E, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 2008;100:475-482
28. Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190. doi 10.1136/ bmj.a1190
29. Dew J, Eden J, Beller E, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-142
30. Uršič-Vrščaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146-151
31. DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy. A cohort analysis. Am J Clin Oncol 2000;23:541-545
32. O'Meara AS, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-762
33. Marttunen MJ, Hietanen P, Pyrhönen S, Titinen A, Ylikorkala O. A prospective study on women with a history of breast cancer and with or without estrogen replacement therapy. Maturitas 2001;39:217-225
34. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, et al. Estrogen replacement therapy for menopausal women with a history of breast cancer. Cancer 2002;95:1817-1826
35. Durna EM, Wren BG, Heller GZ, Leader LR, Sjoblom P, Eden JA. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002;177:347-351
36. Decker DA, Pettinga JE, VanderVelde N, Huang RR, Kestin L, Burdakin JH. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause 2003; 10:277-285
37. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
38. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005;97: 533-535
39. Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 2006;24:3991-3996
40. Osborne CR, Duncan A, Sedlacek S, et al. The addition of hormone therapy to tamoxifen does not prevent hot flushes in women at high risk of developing breast cancer. Breast Cancer Res Treat 2009;116:521-527
41. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem 2001;76:231-238
42. Van Leeuwen FF, Benraadt J, Coeberger WW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452
43. Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2005;112:228-233
44. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006;13: 917-925
45. Cummings SR, Ettinger B, Delmar PG, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;369:697-708
46. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a doubleblind, randomised non-inferiority trial. Lancet Oncol 2009;10:135-146
47. Escande A, Servant N, Rabenoelina F, et al. Regulation of activities of steroid hormone receptors by tibolone and its primary metabolites. J Steroid Biochem Mol Biol 2009;116: 8-14
48. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebocontrolled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int 2009;15:63-69
49. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force. A review of the process. Am J Prev Med 2001;20:21-35
50. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double blind trial of a non-hormonal intervention. Br Med J 1974;I:409-412
51. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flushes. J Clin Oncol 1994;12: 155-158
52. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-793
53. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flushes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101: 337-345
54. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flushes: a randomized controlled trial. Menopause 2008;15:310-318
55. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flushes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366: 818-824
56. Reddy SY, Warner H, Guttuso T Jr, et al. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006;108:41-48
57. Stearns V, Beebe KL, Lyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flushes: a randomized controlled trial. JAMA 2003;289:2827-2834
58. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flushes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-6930
59. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flushes. J Clin Oncol 2002;20:1578-1583
60. Oktem M, Eroglu D, Karahan HN, et al. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective randomized trial. Adv Ther 2007;24:448-461
61. Suvanto-Luukkonen E, Koivunen R, Sundström H, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebocontrolled, double-blind study. Menopause 2005;12:18-26
62. Kalay AE, Demir B, Haberal A, et al. Efficacy of citalopram on climacteric symptoms. Menopause 2007;14:223-229
63. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomised controlled double-blind, crossover trial in a general population. Menopause 2006;13: 568-575
64. Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, doubleblind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114-122
65. Grady D, Cohen B, Tice J, et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes. Obstet Gynecol 2007;109:823-830
66. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flushes after breast cancer. Oncologist 2007;12: 124-135
67. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flushes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063
68. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166
69. Speroff L, Gass M, Constantine G, et al. Efficacy and tolerability of desvenlafaxine for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
70. Wyrwich KW, Spratt DI, Gass M, et al. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008;15:698-705
71. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with the menopause. Am J Obstet Gynecol 2009;200: e1-10
72. Van der Sluijs, Bensoussan A, Liyanage K, Shah S. Women's health during mid-life survey: the use of complementary and alternative medicine by symptomatic women transitioning through menopause in Sydney. Menopause 2007;14: 397-403
73. Nedrew, A, Miller J, Walker M, et al. Complementary and alternative therapies for the management of menopause related symptoms. Arch Intern Med 2006;166:1453-1465
74. Upmalis DH, Lobo R, Bradley L, et al. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2000;7:236-242 (Pubitemid 30445953)
75. Lewis JE, Nickell LA, Thompson LU, et al. A randomized controlled trial of the effect of dietary soy and flaxseed muffins on quality of life and hot flashes during menopause. Menopause 2006;13:631-642
76. Nikander E, Kilkkinen A, Heikkila MM, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213-1220
77. Secreto G, Chiechi LM, Amadori A, et al. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, doubleblind, randomized trial. Maturitas 2004;47: 11-20
78. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18: 1068-1074
79. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized controlled clinical trial. J Clin Oncol 2002;20:1449-1455
80. D'Anna R, Cannata ML, Marini H, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled trial. Menopause 2009;16:301-306
81. Heyerich A, Vervarcke S, Depypere H, et al. A first prospective randomized double-blind placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 2006;54:164-175
82. Hirata JD, Small R, Swiersz LM, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind placebo-controlled trial. Fertil Steril 1997;68:981-986
83. Kupfersztain C, Rotem C, Fagot R, Kaplan B. The immediate effect of natural plant extract, Angelica sinensis and matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet Gynecol 2003;30:203-206
84. Davis SR, Briganti EM, Che RQ, et al. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Med J Aust 2001;174:68-75
85. Hilditch JR, Lewis J, Peter A, et al. A menopause specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175
86. Kwee SH, Tan HH, Marsman A, Wauters C. The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy. Maturitas 2007;58: 83-90
87. Frei-Kleiner S, Schaffner W, Rahlfs VW, et al. Cimicifuga racemosa dried ethanolic-extract in menopausal disorders: a double blind placebocontrolled clinical trial. Maturitas 2005;51: 397-404
88. Van der Sluijs CP, Bensoussan A, Chang E, Baber R. A randomized placebo-controlled trial on the effectiveness of an herbal formula to alleviate menopausal hot flushes. Menopause 2009;16:336-344
89. Haines CJ, Lam PM, Chung TK, et al. A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women. Climacteric 2008;11:244-251
90. Winther K, Rein E, Hedman C. Femal. a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric 2005;8: 162-170
91. Lindh-Åstrand L, Nedstarnd E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2003;48:97-105
92. Daley A, MacArthur C, Mutrie N, Stokes-Lampard H. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;4:CD006108
93. Romani WA, Gallicchio L, Flaws JA. The association between physical activity and hot flash intensity, frequency, and duration in mid-life women.AmJHumBiol 2009;21:127-129
94. Chattha R, Nagarathna R, Padmalatha V, Nagendra HR. Effect of yoga on cognitive functions in climacteric syndrome: a randomised control study. BJOG 2008;115:991-1000
95. Lee MS, Kim JI, Ha JY, Boddy K, Ernst E. Yoga for menopausal symptoms: a systematic review. Menopause 2009;16:602-608
96. Huang MI, Nir Y, Chen B, et al. A randomized controlled pilot study of acupuncture for postmenopausal hot flushes: effect on nocturnal hot flashes and sleep quality. Fertil Steril 2006;86:700-710
97. Vincent A, Barton DL, Mandrekar JN, et al. Acupuncture for hot flushes: a randomized, sham-controlled clinical study. Menopause 2007;14:45-52
98. Deng G, Vickers A, Yeung S, et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol 2007;25:5584-5590
99. Hervik J, Mjåland O. Acupuncture for the treatment of hot flashes in breast cancer patients: a randomized, controlled trial. Breast Cancer Res Treat 2009;116:311-316
100. Borud EK, Alraek T, White A, et al. The effect of TCM acupuncture on hot flushes among menopausal women (ACUFLASH) study: a study protocol of an ongoing multi-centre randomised controlled clinical trial. BMC Compl Alt Med 2007;7:6-13
101. Lee MS, Shin BC, Ernst E. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric 2009;12:16-25
102. Hur M-H, Yang YS, Lee MS. Aromatherapy affects menopausal symptoms in climacteric women: a pilot controlled clinical trial. Evid Based Alternative Med 2007;5: 325-328
103. Jacobs J, Herman P, Heron K, et al. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized trial. J Alt Complem Med 2005;11:21-27
104. Green J, Denham A, Ingram J, Hawkey S, Greenwood R. Treatment of menopausal symptoms by qualified herbal practitioners: a prospective, randomized controlled trial. Fam Prac Adv 2007;24:468-474
105. Freedman RR. Physiology of hot flushes. Am J Hum Biol 2001;13:453-464
106. Freedman RR, Krell W. Reduced thermoregulatory null zone in post-menopausal women with hot flushes. Am J Obstet Gynecol 1999;181:66-70
107. Lipov EG, Lipov S, Joshi JR, Santucci VD, Slavin KV, Beck Vigue SG. Stellate ganglion block may relieve hot flashes by interrupting the sympathetic nervous system. Med Hypotheses 2007;69:759-763
108. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol 2008;9: 523-532
109. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flush studies. J Clin Oncol 2001;19:4280-4290
110. Lipov E, Lipov S, Stark JT. Stellate ganglion blockade provides relief from menopausal hot flushes: a case report series. J Womens Health (Larchmt) 2005;14:737-741
111. Lipov EG, Joshi JR, Xie H, Slavin KV. Updated findings on the effects of stellate-ganglion block on hot flushes and night awakenings. Lancet Oncol 2008;9:819-820
112. Elias M. Cervical sympathetic and stellate ganglion blocks. Pain Physician 2000;3:294-304
113. Wulf H, Maier C. Complications and side effects of stellate ganglion blockade. Results of a questionnaire survey. Anaesthesist 1992;41: 146-151
114. Higa K,Hirata K, Hirota K, Nitahara K, Shono S. Retropharyngeal hematoma after stellate ganglion block: analysis of 27 patients reported in the literature. Anesthesiology 2006;105:1238-1245
115. Abdi S, Zhou Y, Patel N, Saini B, Nelson J. A new and easy technique to block the stellate ganglion. Pain Physician 2004;7:327-331
116. Baumann JM, Middaugh RE, Cawthon MA, Hartshorne MF, Menk EJ, Baysinger C. Radionuclide-anesthetic flow study: a new technique for the study of regional anesthesia. J Nucl Med 1986;27:1487-1489
117. Kapral S, Krafft P, Gosch M, Fleischmann D, Weinstabl C. Ultrasound imaging for stellate ganglion block: direct visualization of puncture site and local anesthetic spread. Reg Anesth 1995;20:323-328
118. Kimura T, Nishiwaki K, Yokota S, Komatsu T, Shimada Y. Severe hypertension after stellate ganglion block. Br J Anaesth 2005;94:840-842 (Pubitemid 40754003)
119. Hardy PA, Wells JC. Extent of sympathetic blockade after stellate ganglion block with bupivacaine. Pain 1989;36:193-196
120. Forouzanfar T, van Kleef M, Weber WE. Radiofrequency lesions of the stellate ganglion in chronic pain syndromes: retrospective analysis of clinical efficacy in 86 patients. Clin J Pain 2000;16:164-168
121. Loprinzi CL, Barton DL, Carns PE. Stellateganglion block: a new treatment for hot flusheš Lancet Oncol 2008;9:506-507